Background on ProAir HFA Discontinuation
Recent information from the internet regarding the discontinuation of ProAir HFA by Teva indicates that the inhaler was ceased on October 1‚ 2022. Alternative options such as authorized generic ProAir HFA and ProAir Digihaler are advised. Additionally‚ the availability of alternative asthma inhalers like Proventil HFA and Ventolin HFA is highlighted as preferred alternatives. Providers have been recommended to actively transition patients to alternative options. Please refer to the provided sources for more details.
Teva’s Decision to Discontinue ProAir HFA
The decision to discontinue ProAir HFA by Teva was officially communicated to Medicaid providers‚ including MaineCare and The Department of Vermont Health Access. Teva ceased the manufacturing of ProAir HFA (albuterol sulfate) Inhalation Aerosol effective October 1‚ 2022. Patients and providers were advised on alternative options like authorized generic ProAir HFA or ProAir Digihaler. In response to the discontinuation‚ Texas Medicaid preferred alternative asthma inhalers such as Proventil HFA and Ventolin HFA for patient care. For additional information‚ providers can contact the specified resources.
Impact of Discontinuation
Following Teva’s decision to discontinue ProAir HFA‚ patients and providers are encouraged to transition to alternative options like authorized generic ProAir HFA and ProAir Digihaler. The availability of alternative asthma inhalers such as Proventil HFA and Ventolin HFA is crucial for ongoing patient care.
Availability of Alternative Inhalers
Following the discontinuation of ProAir HFA‚ alternative options like authorized generic ProAir HFA and ProAir Digihaler are being recommended. Also‚ alternative asthma inhalers such as Proventil HFA and Ventolin HFA are available as preferred alternatives. Providers have been advised to ensure a smooth transition to these alternative options for ongoing patient care.
Recommendations for Healthcare Providers
Providers are advised to transition patients from ProAir HFA to alternative options like authorized generic ProAir HFA or ProAir Digihaler. The availability of alternative asthma inhalers such as Proventil HFA and Ventolin HFA should be considered for ongoing patient care.
Transitioning Patients to Alternative Options
Providers are recommended to transition patients from ProAir HFA to alternative options like authorized generic ProAir HFA or ProAir Digihaler. The availability of alternative asthma inhalers such as Proventil HFA and Ventolin HFA should be considered for ongoing patient care.
Patient Considerations and Side Effects
Common side effects of ProAir HFA may include chest pain‚ fast heartbeats‚ upset stomach‚ vomiting‚ dizziness‚ and headache. Patients should be aware of these potential side effects when transitioning to alternative options.
Common Side Effects of ProAir HFA
Patients using ProAir HFA may experience common side effects such as chest pain‚ fast or pounding heartbeats‚ upset stomach‚ vomiting‚ dizziness‚ feeling shaky or nervous‚ headache‚ back pain‚ body aches‚ cough‚ sore throat‚ sinus pain‚ runny or stuffy nose. It is crucial for patients to be informed about these potential side effects when considering the transition to alternative options.
Communication and Resources
Providers have been notified about the discontinuation of ProAir HFA by Teva‚ and alternative options like authorized generic ProAir HFA and ProAir Digihaler have been recommended. For further guidance and information on the availability of alternatives such as Proventil HFA and Ventolin HFA‚ providers can contact specific resources provided by the Medicaid program.
Provider Contacts and Additional Information
For further information and support regarding the discontinuation of ProAir HFA‚ providers can contact the Department of Vermont Health Access (DVHA) and its pharmacy benefits administrator‚ Change Healthcare‚ at the provided phone number or fax. Additional details on alternative options and transitions to Ventolin HFA can be obtained through the specified channels.
Leave a Reply